IRVINE, Calif., Oct. 13, 2005 (PRIMEZONE) -- "While many fear the lack of investment dollars in the stock market by retiring baby boomers, savvy investors are focusing on the areas where this enormous group will soon be spending their money," stated SmallCap Sentinel analyst, D.R. Clark. "Surely, the diminished income of retired boomers will tighten personal spending and investment but it should simultaneously cause a greater consumption of imperative goods and services, led most obviously by health care."
"Companies are aggressively growing their health care related business plans with research and product development, broadening their revenue-seeking footprint as the boomers head toward their golden years," Clark added.
The informational report "The Silver Tsunami: Baby Boomers and Biotech Breakthroughs" is available at: www.SmallCapSentinel.com
The report will address issues regarding emergent biotechnology potentially affecting drug makers such as Medimmune Inc. (Nasdaq:MEDI), Genentech Inc. (NYSE:DNA) and Novartis AG (NYSE:NVS).
The report will also address Callisto Pharmaceuticals (AMEX:KAL), a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in pre-clinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.
"Callisto's CEO recently stated in a news release that Callisto's underlying medical mission is designed to help patients who have run out of treatment options for certain multi-drug resistant tumors, leukemia and other hard to treat cancers," Clark noted.
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link: http://www.trilogy-capital.com/kal_summary.aspx
Individuals may also register for future reports at:http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by Callisto Pharmaceuticals for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.